In healthcare sector investing, the Vanguard Health Care ETF (VHT) and the State Street SPDR S&P Pharmaceuticals ETF (XPH) represent two distinct approaches to healthcare investment: the former features low costs, high dividends, and broad diversification, making it suitable for investors seeking long-term stable allocation; the latter features concentrated holdings and an equal-weight strategy, offering investors pursuing growth potential greater upside but also accompanied by higher volatility and sector concentration risk. There is no absolute superiority or inferiority between the two; the key lies in whether the investor’s objectives and risk tolerance match the characteristics of the fund.
VHT’s investment scope covers multiple areas including insurance companies, equipment suppliers, and biotechnology, while XPH specifically targets the pharmaceutical manufacturing industry. Investors typically use such tools to obtain defensive characteristics as well as innovation-driven growth opportunities.
From a cost perspective, VHT is the more affordable choice, with an expense ratio of 0.09%, compared to XPH’s expense ratio of 0.35%. In addition, VHT also has a higher dividend level, with a yield of 1.5%, higher than XPH’s 0.5%.
In terms of performance and risk, the differences between the two are equally evident. Over the past five years, XPH’s maximum drawdown was 30.9%, while VHT’s was 17.7%. During the same period, a $1,000 investment in XPH grew to a total return of $1,574, while VHT reached $1,333.
VHT holds 411 securities, covering healthcare (99%) and the technology sector, and adopts a passively managed style. Its largest holdings include Eli Lilly (LLY) at 13.40%, Johnson & Johnson (JNJ) at 8.84%, and AbbVie (ABBV) at 6.45%. The fund was established in 2004, paid $4.72 per share in dividends over the past 12 months, and based on its recent share price of approximately $323.7, its yield is about 1.5%.
XPH is more concentrated, holding 65 securities, all belonging to the healthcare sector, and aims to track the performance of the S&P Pharmaceuticals Select Industry Index. Its largest holdings include Amylyx Pharmaceuticals (AMLX) at 4.19% and MBX Biosciences (MBX) at 3.05%. The fund was established in 2006, paid $0.34 per share in dividends over the past 12 months, and based on its recent share price of approximately $72.3, its yield is about 0.5%.
For investors hoping to gain exposure to the healthcare sector, choosing VHT or XPH depends on which fund better fits their personal investment objectives.
XPH’s pharmaceutical industry focus gives it the potential to achieve excess returns, making it more suitable for growth-oriented investors who prioritize upside potential rather than dividend income and expense ratios. The fund adopts an equal-weight strategy, giving all holdings an opportunity to contribute to the ETF’s returns.
However, XPH is more volatile than VHT, as evidenced by its larger maximum drawdown. Because it focuses on a single industry, the fund is susceptible to downturns in the pharmaceutical industry, such as shocks brought by regulatory or clinical setbacks.
VHT is suitable for investors seeking broad exposure to the healthcare sector, and it is especially a good choice for long-term investors because the fund has a lower expense ratio and a dividend yield far higher than XPH. About 34% of the ETF consists of pharmaceutical companies, and with more than 400 holdings, it therefore has good balance and a high degree of diversification. However, VHT uses market-cap weighting, which means its performance depends mainly on large-cap stocks.
